IntoCell, Inc. (287840.KQ) stock: key figures, P/E, revenue and dividend
Health Care · South Korea
IntoCell, Inc. financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 2.91 bn KRW | 2.30 bn KRW |
| Gross profit | 2.91 bn KRW | 2.30 bn KRW |
| Operating income | -9.79 bn KRW | -10.30 bn KRW |
| EBIT | -9.60 bn KRW | -10.35 bn KRW |
| Net income | -9.91 bn KRW | -10.60 bn KRW |
| Diluted EPS – continuing operations | -668.47 KRW | -706.86 KRW |
Full history since 2022, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About IntoCell, Inc.
IntoCell, Inc. develops protein-drug conjugates for the treatment of cancer. It develops antibody drug conjugates (ADC), fusion albumin drug conjugates, and triple conjugates. The company also develops B7-H3 ADC, which is in preclinical Phase for the treatment of solid cancers, as well as HER3 ADC, 5T4 ADC, and PSMA ADC for solid cancers. In addition, it develops Ortho-Hydroxy Protected Aryl Sulfate (OHPAS), a novel self-immolative group that designs to incorporate various functional groups for linking targeting moieties; and OHPASM Linker-toxin Library, an optimized linker-toxin library for fast delivery of a pre-clinical candidate in novel ADC programs. The company was founded in 2015 and is based in Daejeon, South Korea.
More stocks
- DOMO, INC. (DOMO)
- ESPEY MFG & ELECTRONICS CORP (ESP)
- Thai Nakarin Hospital Public Company Limited (TNH.BK)
- STONERIDGE INC (SRI)
- SBB Tech Co Ltd (389500.KQ)
- James River Group Holdings, Inc. (JRVR)
- Cenra Inc. (3716.TW)
- Biosyent Inc. (RX.V)
- Orilina Properties REIC S.A. (ORILINA.AT)
- EOI Holding (3717.TW)
- Torimbia Socimi S.A. (YTRM.MC)
- Alpha Technology Group Limited Ordinary Shares (ATGL)
Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.